申请人:Allergan, Inc.
公开号:US05300499A1
公开(公告)日:1994-04-05
The present invention provides novel carbonic anhyrase inhibitors represented by the structural formula: ##STR1## wherein R.sub.1 and R.sub.2 are, for example, independently (a) hydrogen; or (b) OR.sub.4, wherein R.sub.4 is hydrogen or C.sub.1-7 alkyl; or (c) NR.sub.5 R.sub.6, wherein R.sub.5 and R.sub.6 are independently hydrogen, or C.sub.1-7 alkyl, or C.sub.1-7 alkyl substituted with one or more halogen or OR.sub.4 ; or (d) --COR.sub.7, wherein R.sub.7 is hydrogen, C.sub.1-7 alkyl, or NR.sub.5 R.sub.6 ; or (e) --SR.sub.8, wherein R.sub.8 is hydrogen or C.sub.1-7 alkyl, or C.sub.1-7 alkyl substituted with one or more halogen, or OR.sub.4 ; or (f) C.sub.1-7 alkyl, or C.sub.1-7 alkyl substituted with one or more halogen, or OR.sub.4 or NR.sub.5 R.sub.6 ; or (g) R.sub.1 and R.sub.2 are together (i) .dbd.O, or (ii) .dbd.NOR.sub.8 or (iii) .dbd.S; and R.sub.3 is (h) C.sub.1-7 alkyl or C.sub.1-7 substituted with one or more halogen, OR.sub.4 or NR.sub.5 R.sub.6.
本发明提供了新的碳酸酐酶抑制剂,其结构式表示为:##STR1## 其中R.sub.1和R.sub.2可以独立地为(a)氢;或(b)OR.sub.4,其中R.sub.4为氢或C.sub.1-7烷基;或(c)NR.sub.5R.sub.6,其中R.sub.5和R.sub.6独立地为氢、C.sub.1-7烷基或C.sub.1-7烷基上带有一个或多个卤素或OR.sub.4取代基;或(d)--COR.sub.7,其中R.sub.7为氢、C.sub.1-7烷基或NR.sub.5R.sub.6;或(e)--SR.sub.8,其中R.sub.8为氢或C.sub.1-7烷基,或C.sub.1-7烷基上带有一个或多个卤素或OR.sub.4取代基;或(f)C.sub.1-7烷基,或C.sub.1-7烷基上带有一个或多个卤素、OR.sub.4或NR.sub.5R.sub.6取代基;或(g)R.sub.1和R.sub.2在一起为(i).dbd.O,或(ii).dbd.NOR.sub.8或(iii).dbd.S;R.sub.3为(h)C.sub.1-7烷基或C.sub.1-7烷基上带有一个或多个卤素、OR.sub.4或NR.sub.5R.sub.6取代基。